H1N1 vax monitoring flags potential risks

The CDC says that their monitoring programs have uncovered a very small increased risk for Guillain-Barre syndrome, Bell's palsy and thrombocytopenia among people who were injected with the H1N1 vaccine. But the increased risk is so small, the CDC says it can't tell if the apparent increase in danger is the result of a problem with the vaccine or simply the result of better monitoring. "Because the effects are so small, it is hard to say whether it is due to chance or a real effect," said Dr. Stephen Redd, director of the CDC's influenza coordination unit. Story

Suggested Articles

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.

GlaxoSmithKline’s vaccines unit has been a bright spot for the company, but its performance doesn’t make it immune to staff cuts.

Researchers had high hopes for a HIV vaccine candidate made up of components supplied by GlaxoSmithKline and Sanofi, but it didn't work.